Hummingbird Bioscience is an innovative therapeutics company with a proprietary rational antibody discovery platform and deep experience in the application of integrative genomics and proteomics. We develop precision therapeutic antibodies to clinical proof-of-concept for patients with the highest unmet need.

Hummingbird Bioscience has developed a pipeline of highly promising oncology and immuno-oncology assets, and has established discovery collaborations with leading partners with the following approaches:
  • Novel, integrative approaches to tumor biology
    Recognition of the importance of both tumor evolution and evasion of immune response as a key “hallmark of cancer” has provided a wide new class of targets. Building on these insights, Hummingbird is developing a comprehensive framework to systematically address the barriers to an effective immune response in every patient. 
  • Rational Antibody Discovery Platform
    A highly innovative systems immunology and computational structural biology approach that enables precise targeting of epitopes and mechanism of action
  • Data and model driven translational medicine and biomarker identification
    Mechanism driven -omics analysis informs selection of appropriate pre-clinical models, role of tumor heterogeneity and down-stream biomarker development 

Recent News

  • 25 February 2019 Hummingbird Bioscience Awarded $13.1 Million Grant by the Cancer Prevention and Research Institute of Texas (CPRIT) (Full Press Release)

  • 18 February 2019 Hummingbird Bioscience Announces Nobel Laureate Dr. James Allison and Dr. Padmanee Sharma Join its Scientific Advisory Board (Full Press Release)

  • 9 November 2018 Hummingbird Bioscience to present data on HMBD-001-10D1 at the EORTC-NCI-AACR's 30th Annual Meeting (Full Press Release)
  • 5 November 2018 Hummingbird Bioscience to present data on HMBD-002-V4 at the Society for Immunotherapy of Cancer (SITC)'s 33rd Annual Meeting (Full Press Release)

  • 10 April 2018 Hummingbird Bioscience to present data on HMBD-002-V4 at the American Association for Cancer Research (AACR) 2018 Meeting (Full Press Release)
  • 25 February 2018 Hummingbird Bioscience is featured on Biotech Strategy Blog discussing its CD47 bispecific pipeline (Full Press Release)

  • 4 December 2017 Hummingbird Bioscience to present data on HMBD-004A at the 59th American Society of Hematology (ASH) Annual Meeting (Full Press Release)
  • 3 May 2017 Hummingbird Bioscience announces it has closed a venture funding round of an undisclosed amount from Decheng Capital (Full Press Release)